Form 4: NHC Director Sells 7,500 Shares Under 10b5-1 Plan

National Healthcare Corp. Director Emil E. Hassan sold 7,500 shares of common stock for approximately $1.04 million under a pre-arranged trading plan.

Summary

• Emil E. Hassan, a Director of National Healthcare Corp. (NHC), reported the disposition of 7,500 shares of NHC common stock.
• The transaction occurred on November 25, 2025, with shares sold at a price of $138.5164 per share.
• The total value of the shares sold was approximately $1,038,873.
• Following this transaction, Mr. Hassan directly beneficially owns 65,595 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Mr. Hassan also holds various stock options, including 7,500 options from each of the 2021, 2022, 2023, 2024, and 2025 grants, with exercise prices ranging from $55.75 to $96.03.

Sentiment

Score: 4

Explanation: A director's sale of shares, even if pre-planned under a 10b5-1 plan, can be viewed with slight caution by investors. However, the remaining significant holdings and the pre-scheduled nature of the transaction mitigate strong negative sentiment.

Negatives

• A director selling a significant number of shares, even under a pre-arranged plan, could be interpreted by some market participants as a signal, potentially impacting investor sentiment.

Risks

• Potential for negative market perception or a temporary dip in investor confidence due to insider selling, despite the transaction being pre-planned.

Future Outlook

NA

Industry Context

This is an insider transaction report and does not directly provide information on broader industry trends. However, general market sentiment towards the healthcare sector can influence how such insider activity is perceived by investors.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, potentially influencing investor confidence or the company's share price, despite the pre-planned nature of the transaction.

Key Dates

Recommendation

While an insider sale can sometimes signal a lack of confidence, this transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily based on new, adverse material information. The director still retains a substantial number of shares and options, indicating continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future insider activity and company performance without immediate alarm.

Keywords

National Healthcare Corp, NHC, Insider Trading, Form 4, Stock Sale, Director Transaction, Emil E. Hassan, Equity Disposition, 10b5-1 Plan